Catalyst Pharma: Upside Potential Amid Patent Infringement Concerns


Catalysts Pharmaceuticals, Inc. (NASDAQ:CPRX) reported product revenue of $57.24 million in Q3 2022, beating Wall Street estimates by $3.55 million. The company’s earnings per share (EPS) of $0.20 beat estimates by $0.01. CPRX’s share price has grown 192.28% (YoY) with the stock trading 29.8% below the 52-week high of $22.11.

Gross Profit growth since 2018

Seeking Alpha

Leave a Reply

Your email address will not be published. Required fields are marked *